Table 2.
Human Breast Cancer Models ABBV-176; N = 3 Screen Study
| Model ID | PRLR Density vs MCF7 | Drug Dosesa | ABBV-176 Efficacyb | ER/PR/HER2 BRCA Status |
|---|---|---|---|---|
| CTG-1124 | 0.15 | 0.2 | High (84%) |
ER+/PR+ BRCA 1 def |
| CTG-0012 | 0.75 | 0.5 | High (90%) |
TNBC BRCA 1 def |
| CTG-0869 | 0.8 | 0.5 | High (93%) |
TNBC BRCA 1 mut |
| CTG-0670 | 1.64 | 0.5 | High (91%) |
TNBC BRCA 1 def, BRCA 2 mut |
| CTG-0033c | 2.06 | 0.2 | High (79%) |
HER2+ BRCA n.d. |
| CTG-1171 | 0.42 | 0.2 | High (82%) |
TNBC BRCA 1, 2 mut |
| CTG-1019 | 0.37 | 0.2 | High (83%) |
TNBC BRCA 1, 2 mut |
| CTG-1242 | 3.83 | 0.2 | High (83%) |
TNBC BRCA n.d. |
| CTG-0052 | 0.46 | 0.2 | Moderate (59%) |
TNBC BRCA wild type |
| CTG-0017 | 0.27 | 0.2 | Moderate (62%) |
TNBC BRCA 1, 2 mut |
| CTG-1520 | 0.56 | 0.5 | Low (48%) |
TNBC BRCA wild type |
BRCA breast cancer DNA associated repair gene, def deficient, ER estrogen receptor, HER2 human epidermal growth factor receptor 2, IP intraperitoneal, mut mutation, n.d. not determined, PR progesterone receptor, TGI tumor growth inhibition, TNBC triple negative breast cancer
aDoses were administered IP Q7D × 3, at the dose level indicated in mg/kg
bLow = 25–50% TGI, Moderate = 50–75% TGI, High > 75% TGI compared to control PBD ADC treated group (p < 0.0001)
cThis study was performed with larger size treatment groups (N = 6)